Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inspire Medical (INSP) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Inspire common stock between August 6, 2024 through August 4, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

• Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Inspire common stock between August 6, 2024 through August 4, 2025, both dates inclusive (the “Class Period”). Investors have until January 5, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  

Allegation Details:

• The Inspire Medical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) the Inspire V launch was a disaster because demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment; and (ii) contrary to defendants’ statements assuring investors that Inspire Medical had taken all necessary steps to ensure a successful launch and, later, that the launch was in fact proceeding successfully – Inspire Medical had failed to complete basic tasks that were essential predicates to launch.
  
  
• The Inspire Medical investor class action alleges that on August 4, 2025, Inspire Medical revealed that the Inspire V launch was facing an “elongated timeframe” due to a number of previously undisclosed headwinds. “[M]any centers did not complete the training, contracting and onboarding criteria required prior to the purchase and implant of [Inspire V],” the complaint alleges. Defendants further admitted that, although Inspire V’s CPT code had been approved for Medicare patients, “software updates for claims submissions and processing did not take effect until July 1,” which meant that “implanting centers would not be able to bill for those procedures until July 1,” the lawsuit alleges. Finally, the lawsuit claims that investors also learned for the first time that the Inspire V rollout was plagued by poor demand resulting from excess inventory. As a result, Inspire Medical reduced its 2025 earnings guidance by more than 80%, the Inspire Medical investor class action alleges. On this news, the price of Inspire Medical’s common stock declined more than 32%, the complaint alleges.
  

Next Steps:

• If you purchased or otherwise acquired Inspire Medical shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
  

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com